Giraffe Bio raises $6.4M to squeeze more copper from existing mines
What's the deal? Giraffe Bio, a startup making mine-specific biomolecules for mineral processing, has raised a $6.4 million seed round led by Orion Industrial VenturesDealroom has a profile for this one. Try Dealroom →. BHP VenturesDealroom has a profile for this one. Try Dealroom →, Twynam, Air CapitalDealroom has a profile for this one. Try Dealroom →, and Baruch Future VenturesDealroom has a profile for this one. Try Dealroom → also took part.
What's the endgame? The company engineers microbes in bioreactors to produce compounds tailored to each mine's mineral content, then feeds them into existing flotation processes. Co-founder and chief executive officer Alejandro Buffo Sempé said this can recover "up to 5% more copper" — significant in an industry where operators treat 1% to 2% as a win.
Why now? Copper sits in the middle of several spending cycles at once: grid upgrades, electric transport, and AI data center buildouts. Giraffe Bio points to estimates that copper supply could fall 25% short of demand by 2040.
How is it different? Rivals such as Endolith and Ceibo mostly deploy live microbes into heap-leaching operations. Giraffe Bio instead targets flotation, a core processing step, with biomolecules it says bind selectively to copper-bearing minerals. The same platform could replace more toxic reagents and later be adapted for gold and silver.
What could go wrong? The 5% claim must hold at commercial scale. Mining plants are reluctant to redesign flowsheets around biological systems or add complexity that creates variable output.
The signal: The round ranks in the 97th percentile for all-time seed deals in deep tech in Argentina, across a sample of 184. It reflects a shift in mining: with only 0.3% of prospective mines panning out, the sector increasingly treats supply as a chemistry problem, not just a geology one.
Read more: startupnews.fyi
Image credit: docentjoyce
